Don't Miss News
Welcome to Neuren Pharmaceuticals (www.neurenpharma.com; ASX:NEU). Neuren is a Melbourne-based company at the forefront of efforts to develop effective treatments for rare, paediatric neurodevelopmental disorders. Over the last few years, they’ve successfully steered their first drug (Trofinetide) into Phase 3 clinical trials (the last stage before approval) for the treatment of Rett syndrome. The final …
We are proud to collaborate with the Angelman Syndrome Foundation, the Dup15q Alliance in Linking Angelman and Dup15q Data for Expanded Research (LADDER).